Universal Vision Biotechnology Co Ltd

Universal Vision Biotechnology Co Ltd maintains a strong liquidity position with a current ratio of 2.92, indicating the company can cover its short-term liabilities more than two and a half times over with its current assets. However, the company's net cash position is negative after subtracting total debt, which suggests a potential liquidity risk. The company's debt-to-equity ratio is 0.26, which is relatively low, indicating a conservative capital structure. In terms of profitability, the company's return on equity (ROE) is 25.92%, and its return on assets (ROA) is 17.11%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures suggest the company is performing well compared to the industry's preferred metrics. The company's revenue is primarily concentrated in the Taiwan market, where it operates its businesses. The company's operations are not diversified across multiple geographic regions, which could expose it to regional economic or regulatory risks. The company's growth trajectory is not explicitly detailed in the provided data, but the operating cash flow of 1.666 billion TWD and free cash flow of 399.131 million TWD suggest the company is generating sufficient cash to support operations and potentially fund growth initiatives. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could affect its liquidity position. However, the dilution risk is low, suggesting that the company is not expected to issue additional shares that could dilute existing shareholders' equity in the near term. Recent events and filings do not provide specific details on the company's recent activities or strategic moves. The company's financial performance and risk profile are based on the latest available financial data and analyst estimates.